SG10202108879SA - TARGETED TGFβ INHIBITION - Google Patents

TARGETED TGFβ INHIBITION

Info

Publication number
SG10202108879SA
SG10202108879SA SG10202108879SA SG10202108879SA SG10202108879SA SG 10202108879S A SG10202108879S A SG 10202108879SA SG 10202108879S A SG10202108879S A SG 10202108879SA SG 10202108879S A SG10202108879S A SG 10202108879SA SG 10202108879S A SG10202108879S A SG 10202108879SA
Authority
SG
Singapore
Prior art keywords
tgfβ inhibition
targeted
targeted tgfβ
inhibition
tgfβ
Prior art date
Application number
SG10202108879SA
Other languages
English (en)
Inventor
Kin-Ming Lo
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SG10202108879SA publication Critical patent/SG10202108879SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
SG10202108879SA 2014-02-10 2015-02-10 TARGETED TGFβ INHIBITION SG10202108879SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461938048P 2014-02-10 2014-02-10

Publications (1)

Publication Number Publication Date
SG10202108879SA true SG10202108879SA (en) 2021-09-29

Family

ID=52988007

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202108879SA SG10202108879SA (en) 2014-02-10 2015-02-10 TARGETED TGFβ INHIBITION
SG11201606577YA SG11201606577YA (en) 2014-02-10 2015-02-10 TARGETED TGFβ INHIBITION

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201606577YA SG11201606577YA (en) 2014-02-10 2015-02-10 TARGETED TGFβ INHIBITION

Country Status (27)

Country Link
US (4) US9676863B2 (hr)
EP (2) EP3889172B1 (hr)
JP (2) JP6731346B2 (hr)
KR (1) KR102363008B1 (hr)
CN (2) CN113549159A (hr)
AU (3) AU2015213988B2 (hr)
BR (1) BR112016014952A2 (hr)
CA (1) CA2934979A1 (hr)
CL (1) CL2016002017A1 (hr)
CY (1) CY1124408T1 (hr)
DK (2) DK3889172T3 (hr)
ES (1) ES2876430T3 (hr)
HR (1) HRP20210977T1 (hr)
HU (1) HUE054873T2 (hr)
IL (2) IL246968B (hr)
LT (1) LT3105246T (hr)
MX (2) MX2016010067A (hr)
NZ (1) NZ721364A (hr)
PE (2) PE20210168A1 (hr)
PH (1) PH12016501549A1 (hr)
PL (1) PL3105246T3 (hr)
PT (1) PT3105246T (hr)
RS (1) RS62038B1 (hr)
RU (2) RU2021114500A (hr)
SG (2) SG10202108879SA (hr)
SI (1) SI3105246T1 (hr)
WO (1) WO2015118175A2 (hr)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015027082A1 (en) 2013-08-22 2015-02-26 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
PE20210168A1 (es) 2014-02-10 2021-01-28 Merck Patent Gmbh INHIBICION DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGFß)
WO2016040880A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
BR112017019559B1 (pt) 2015-03-13 2020-08-04 Cytomx Therapeutics, Inc Anticorpos anti-pdl1, anticorpos anti-pdl1 ativáveis, e métodos de uso destes
US10167334B2 (en) 2015-04-03 2019-01-01 Xoma Technology Ltd. Treatment of cancer using anti-TGF-BETA and PD-1 antibodies
MA44594B1 (fr) 2015-05-29 2020-09-30 Memorial Sloan Kettering Cancer Center Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
EP3331550B1 (en) 2015-08-04 2022-11-02 Acceleron Pharma Inc. Composition for treating myeloproliferative disorders
WO2017020291A1 (en) * 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
KR20180063885A (ko) * 2015-09-24 2018-06-12 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 전이 감소를 위한 방법 및 조성물
US11583593B2 (en) 2016-01-14 2023-02-21 Synthis Therapeutics, Inc. Antibody-ALK5 inhibitor conjugates and their uses
CN109069638B (zh) 2016-03-24 2022-03-29 璟尚生物制药公司 用于癌症治疗的三特异性抑制剂
CN109312408B (zh) * 2016-05-17 2022-12-23 豪夫迈·罗氏有限公司 用于诊断和供免疫疗法中使用的基质基因签名
MX2018014387A (es) 2016-05-27 2019-03-14 Agenus Inc Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
ES2905663T3 (es) * 2016-08-12 2022-04-11 Merck Patent Gmbh Terapia de combinación para el cáncer
KR102617453B1 (ko) 2016-09-19 2023-12-26 현대모비스 주식회사 보조 표지판 인식 장치 및 그 방법
AU2017336546A1 (en) 2016-09-27 2019-05-02 Epicentrx, Inc. Immunomodulatory fusion proteins
US10844119B2 (en) 2016-10-11 2020-11-24 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
CA3046082A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Antibodies and methods of use thereof
SI3551660T1 (sl) 2016-12-07 2024-02-29 Agenus Inc. Protitelesa proti antictla-4 in načini njihove uporabe
EP3565839A4 (en) 2017-01-05 2021-04-21 Gensun Biopharma Inc. CHECKPOINT REGULATOR ANTAGONISTS
BR112019013924A2 (pt) * 2017-01-07 2020-02-11 Merck Patent Gmbh Regimes de dosagem e formas de dosagem para inibição de tgf-beta direcionada
EP4382913A2 (en) * 2017-01-10 2024-06-12 Precigen, Inc. Modulating expression of polypeptides via new gene switch expression systems
GB201700567D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
EA201991696A1 (ru) 2017-01-13 2020-02-05 Эйдженус Инк. Т-клеточные рецепторы, связывающиеся с ny-eso-1, и способы их применения
CN110573532B (zh) 2017-03-02 2024-04-16 加拿大国家研究委员会 TGF-β 受体胞外域融合分子及其用途
CN110494161A (zh) * 2017-03-30 2019-11-22 默克专利股份有限公司 用于治疗癌症的抗pd-l1抗体和dna-pk抑制剂的组合
WO2018191502A2 (en) 2017-04-13 2018-10-18 Agenus Inc. Anti-cd137 antibodies and methods of use thereof
FI3618863T3 (fi) 2017-05-01 2023-09-01 Agenus Inc Anti-TIGIT-vasta-aineita ja menetelmiä niiden käyttämiseksi
EP3628049B1 (en) 2017-05-04 2023-05-10 Acceleron Pharma Inc. Tgf-beta receptor type ii fusion proteins and uses thereof
AU2018266103B2 (en) * 2017-05-09 2024-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination PDL1 and TGF-beta blockade in patients with HPV+ malignancies
TW201900674A (zh) 2017-05-12 2019-01-01 大陸商江蘇恆瑞醫藥股份有限公司 含有ＴＧＦ－β受體的融合蛋白及其醫藥用途
WO2018222901A1 (en) 2017-05-31 2018-12-06 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
BR112019025188A2 (pt) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
CN111278854A (zh) 2017-09-04 2020-06-12 艾吉纳斯公司 与混合谱系白血病(mll)特异性磷酸肽结合的t细胞受体和其使用方法
JP2020536518A (ja) 2017-09-27 2020-12-17 エピセントアールエックス，インコーポレイテッド 免疫調節融合タンパク質
EP3707510B1 (en) * 2017-11-06 2024-06-26 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for cancer
EP3720881A1 (en) * 2017-12-08 2020-10-14 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
WO2019173692A2 (en) 2018-03-09 2019-09-12 Agenus Inc. Anti-cd73 antibodies and methods of use thereof
KR20200131270A (ko) 2018-03-14 2020-11-23 메르크 파텐트 게엠베하 대상체에서의 암을 치료하기 위한 화합물 및 이의 용도
WO2019178364A2 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
TW202012430A (zh) 2018-04-26 2020-04-01 美商艾吉納斯公司 熱休克蛋白質－結合之胜肽組成物及其使用方法
US20220372107A1 (en) * 2018-05-03 2022-11-24 Acceleron Pharma Inc. MULTISPECIFIC BINDERS OF TGFBeta-SUPERFAMILY LIGANDS AND USES THEREOF
CA3099325A1 (en) * 2018-05-03 2019-11-07 Acceleron Pharma Inc. Novel binders of tgf.beta.-superfamily ligands and uses thereof
AU2019264229A1 (en) 2018-05-04 2020-12-03 Merck Patent Gmbh Combined inhibition of PD-1/PD-L1, TGFβ and DNA-PK for the treatment of cancer
KR20210009339A (ko) * 2018-05-15 2021-01-26 메르크 파텐트 게엠베하 치료 나이브 대상체의 암 치료에 사용하기 위한 표적화된 TGF-β 억제를 위한 투약 레지멘
JP2021524447A (ja) 2018-05-17 2021-09-13 ボルト バイオセラピューティクス、インコーポレーテッド イムノコンジュゲート
WO2019241353A1 (en) * 2018-06-13 2019-12-19 Merck Patent Gmbh Treatment of stage iii nsclc and mitigation of pathological conditions associated with the treatment
WO2019242505A1 (zh) 2018-06-17 2019-12-26 上海健信生物医药科技有限公司 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
JP2021528399A (ja) * 2018-06-22 2021-10-21 メルク パテント ゲーエムベーハー 胆道癌を治療する際に使用するための標的ＴＧＦ−β阻害のための投薬計画
CN112638401A (zh) 2018-06-29 2021-04-09 璟尚生物制药公司 抗肿瘤拮抗剂
CN112638374A (zh) * 2018-07-02 2021-04-09 默克专利有限公司 用于治疗晚期非小细胞肺癌的采用靶向的TGF-β抑制的组合疗法
DE202019005887U1 (de) 2018-07-03 2023-06-14 Marengo Therapeutics, Inc. Anti-TCR-Antikörpermoleküle und Verwendungen davon
KR20210042909A (ko) * 2018-07-09 2021-04-20 프레시전 인코포레이티드 융합 구조물 및 그의 이용 방법
AU2019325593A1 (en) * 2018-08-22 2021-03-18 Merck Patent Gmbh Treatment of triple negative breast cancer with targeted TGF-B inhibition
JP7465272B2 (ja) 2018-09-27 2024-04-10 マレンゴ・セラピューティクス，インコーポレーテッド Ｃｓｆ１ｒ／ｃｃｒ２多特異性抗体
EP3873611A1 (en) 2018-11-01 2021-09-08 Merck Patent GmbH Anti-tim-3 antibodies
AU2019372436A1 (en) * 2018-11-01 2021-05-20 Merck Patent Gmbh Methods of administering anti-TIM-3 antibodies
MX2021005018A (es) * 2018-11-09 2021-06-15 Jiangsu Hengrui Medicine Co Composicion farmaceutica de proteina de fusion del receptor tgf-?, y uso de la misma.
US20210369776A1 (en) * 2018-12-06 2021-12-02 Guangdong Tcrcure Biopharma Technology Co., Ltd. Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints
JP2022521937A (ja) 2019-02-21 2022-04-13 マレンゴ・セラピューティクス，インコーポレーテッド ＮＫｐ３０に結合する抗体分子およびその使用
WO2020172571A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
AU2020224680A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cells and uses thereof to treat autoimmune disorders
WO2020190734A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting pd-l1
CN114206926B (zh) * 2019-06-10 2022-06-17 山东博安生物技术股份有限公司 抗PDL1和TGFβ的双功能融合蛋白及其用途
AU2020291014A1 (en) 2019-06-13 2022-01-27 Bolt Biotherapeutics, Inc. Aminobenzazepine compounds, immunoconjugates, and uses thereof
CN110218260A (zh) * 2019-06-24 2019-09-10 王跃驹 植物作为宿主在表达m7842中的应用
CN114340735A (zh) * 2019-06-28 2022-04-12 璟尚生物制药公司 突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂
US20210107969A1 (en) * 2019-07-09 2021-04-15 The Johns Hopkins University Molecules, compositions and methods for treatment of cancer
CN114401995A (zh) * 2019-08-15 2022-04-26 南特比奥有限公司 TGF-β陷阱
PE20221151A1 (es) 2019-08-30 2022-07-18 Agenus Inc Anticuerpos anti-cd96 y sus metodos de uso
WO2021037184A1 (zh) 2019-08-30 2021-03-04 正大天晴药业集团南京顺欣制药有限公司 一种靶向PD-L1和TGF-β的融合蛋白及其用途
US20220313835A1 (en) 2019-09-03 2022-10-06 Bolt Biotherapeutics, Inc. Aminoquinoline compounds, immunoconjugates, and uses thereof
JP2022547066A (ja) 2019-09-04 2022-11-10 ボルト バイオセラピューティクス、インコーポレーテッド 免疫結合体合成方法
CN112442132A (zh) * 2019-09-05 2021-03-05 复旦大学 靶向肿瘤的重组双功能融合蛋白及其应用
EP4023672A1 (en) * 2019-09-30 2022-07-06 Harbour Biomed (Shanghai) Co., Ltd Anti-pd-l1 antigen binding protein, and application thereof
MX2022003740A (es) 2019-09-30 2022-05-02 Bolt Biotherapeutics Inc Inmunoconjugados de aminobenzazepina unidos a amida y usos de estos.
CN114616251B (zh) * 2019-10-21 2024-05-24 南京维立志博生物科技有限公司 靶向PD-1和TGFβ的重组蛋白
WO2021081407A1 (en) 2019-10-25 2021-04-29 Bolt Biotherapeutics, Inc. Thienoazepine immunoconjugates, and uses thereof
BR112022007787A2 (pt) 2019-11-01 2022-07-05 Ares Trading Sa Inibição combinada de pd-1, tgfss e atm juntamente com radioterapia para o tratamento de câncer
CA3155219A1 (en) 2019-11-05 2021-05-14 Merck Patent Gmbh Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer
WO2021093760A1 (zh) * 2019-11-12 2021-05-20 江苏恒瑞医药股份有限公司 含有TGF-β受体的融合蛋白及其医药用途
TWI772984B (zh) * 2019-11-27 2022-08-01 大陸商上海岸邁生物科技有限公司 TGFβ/PD-L1雙特異性結合蛋白
EP4073124A4 (en) * 2019-12-11 2024-01-24 Wuxi Biologics Ireland Limited BIFUNCTIONAL ANTIBODIES AGAINST PD-L1 AND TGFBETA
US20230043290A1 (en) 2019-12-20 2023-02-09 Ares Trading S.A. Igg:tgfbetarii fusion protein composition
EP3838260A1 (en) 2019-12-20 2021-06-23 Ares Trading S.A. Igg:tgf rii fusion protein composition
CN113004414B (zh) * 2019-12-20 2022-09-06 广东菲鹏制药股份有限公司 抗PD1和TGFβ的双功能抗体及其制备方法，以及含有其的药物组合物
CN113121699A (zh) * 2019-12-30 2021-07-16 国典(北京)医药科技有限公司 Pttrap1双特异性融合蛋白及其应用
EP4084821A4 (en) 2020-01-03 2024-04-24 Marengo Therapeutics, Inc. CD33-BINDING MULTIFUNCTIONAL MOLECULES AND THEIR USES
EP4093772A1 (en) 2020-01-21 2022-11-30 Bolt Biotherapeutics, Inc. Anti-pd-l1 antibodies
EP4093510A1 (en) 2020-01-21 2022-11-30 Bolt Biotherapeutics, Inc. Anti-pd-l1 antibodies
CN115135675A (zh) * 2020-02-18 2022-09-30 南京金斯瑞生物科技有限公司 融合蛋白及其用途
CN115175942A (zh) * 2020-02-25 2022-10-11 上海药明生物技术有限公司 一种双功能融合蛋白及其用途
EP4056596A4 (en) * 2020-03-20 2023-01-25 RemeGen Co., Ltd. BISPECIFIC FUSION PROTEIN AND USE THEREOF
JP2023521465A (ja) 2020-04-14 2023-05-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド ＩＣＯＳ抗体とＰＤ－Ｌ１抗体ＴＧＦ－β－受容体融合タンパク質とに基づく癌の併用治療
WO2021209458A1 (en) 2020-04-14 2021-10-21 Ares Trading S.A. Combination treatment of cancer
CN115843312A (zh) 2020-04-24 2023-03-24 马伦戈治疗公司 结合至t细胞相关癌细胞的多功能性分子及其用途
US11634477B2 (en) 2020-04-28 2023-04-25 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof
JP2023524092A (ja) 2020-05-01 2023-06-08 ボルト バイオセラピューティクス、インコーポレーテッド 抗デクチン－２抗体
JP2023524271A (ja) 2020-05-08 2023-06-09 ボルト バイオセラピューティクス、インコーポレーテッド エラスターゼ－基質ペプチドリンカーイムノコンジュゲート、及びそれらの使用
KR20230028795A (ko) * 2020-06-26 2023-03-02 소렌토 쎄라퓨틱스, 인코포레이티드 면역조절 융합 단백질을 발현하는 종양용해 단순헤르페스 바이러스 (hsv)
JP2023534738A (ja) 2020-07-24 2023-08-10 ▲邁▼威（上海）生物科技股▲フン▼有限公司 ＴＧＦ－β ＲＩＩ突然変異体及びその融合タンパク質
US11028174B1 (en) 2020-07-28 2021-06-08 Lepu Biopharma Co., Ltd. Bifunctional molecules targeting PD-L1 and TGF-β
JP2023540436A (ja) * 2020-07-28 2023-09-25 レプ バイオファーマ カンパニー リミテッド Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子
WO2022042537A1 (zh) * 2020-08-24 2022-03-03 江苏恒瑞医药股份有限公司 TGF-β受体的融合蛋白与多靶点酪氨酸激酶抑制剂联合在制备抗肿瘤药物中的用途
WO2022047046A1 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Methods of detecting trbc1 or trbc2
CA3190755A1 (en) 2020-08-26 2022-03-03 Andreas Loew Multifunctional molecules that bind to calreticulin and uses thereof
KR20230074144A (ko) 2020-08-26 2023-05-26 마렝고 테라퓨틱스, 인크. NKp30에 결합하는 항체 분자 및 이의 용도
CN115884989A (zh) * 2020-08-31 2023-03-31 杭州九源基因工程有限公司 靶向PD-L1和TGFβ的双功能融合蛋白及其制备方法与应用
EP4165086A1 (en) * 2020-09-16 2023-04-19 Suzhou Neologics Bioscience Co., Ltd. Pd-l1 antibodies, fusion proteins, and uses thereof
WO2022057061A1 (en) * 2020-09-16 2022-03-24 Suzhou Neologics Bioscience Co., Ltd. Pd-l1 antibodies, fusion proteins, and uses thereof
CN116390940A (zh) * 2020-09-23 2023-07-04 海正生物制药有限公司 Tgfbr2-ecd突变体及包含其的融合蛋白与应用
CN116323657B (zh) * 2020-09-24 2023-12-08 上海齐鲁制药研究中心有限公司 同时靶向PD-L1和TGFβ的双功能分子及其医药用途
CN114349867B (zh) * 2020-10-14 2024-05-28 广东菲鹏制药股份有限公司 融合蛋白及其应用
AU2021370991A1 (en) 2020-11-02 2023-06-22 Ares Trading S.A. Combination treatment of cancer
AU2021372815A1 (en) 2020-11-02 2023-06-22 Ares Trading S.A. Combination treatment of cancer
CN114573701A (zh) * 2020-12-02 2022-06-03 上海华奥泰生物药业股份有限公司 抗PD-L1/TGF-β双功能抗体及其用途
WO2022125891A2 (en) 2020-12-11 2022-06-16 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
US20220195066A1 (en) 2020-12-11 2022-06-23 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
IL303491A (en) 2020-12-11 2023-08-01 Bolt Biotherapeutics Inc Anti-PD-L1 immunoconjugates and uses thereof
CN116917334A (zh) 2021-02-22 2023-10-20 浙江道尔生物科技有限公司 一种具有抗癌活性的多结构域融合蛋白
MX2023010067A (es) 2021-03-02 2023-09-06 Glaxosmithkline Ip Dev Ltd Piridinas sustituidas como inhibidores de dnmt1.
JP2024512056A (ja) 2021-03-26 2024-03-18 ボルト バイオセラピューティクス、インコーポレーテッド ２－アミノ－４－カルボキサミド－ベンゾアゼピン免疫複合体、及びその使用
EP4313162A1 (en) 2021-03-26 2024-02-07 Bolt Biotherapeutics, Inc. 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
CA3218697A1 (en) 2021-05-03 2022-11-10 Merck Patent Gmbh Her2 targeting fc antigen binding fragment-drug conjugates
CN114773485B (zh) * 2021-05-11 2024-05-17 江苏先声药业有限公司 抗人PD-L1抗体和TGFβRII的双功能融合蛋白分子
WO2022248380A1 (en) 2021-05-25 2022-12-01 Merck Patent Gmbh Egfr targeting fc antigen binding fragment-drug conjugates
AU2022288571A1 (en) 2021-06-07 2024-01-04 Ares Trading S.A. Combination treatment of cancer
WO2023027561A1 (ko) * 2021-08-27 2023-03-02 세라노틱스(주) B7-h3 및 tgfβ에 특이적으로 결합하는 이중 특이적 분자 및 이의 용도
US11945856B2 (en) 2022-01-28 2024-04-02 35Pharma Inc. Activin receptor type IIB variants and uses thereof
CN114990129B (zh) * 2022-05-11 2023-02-03 北京贝来生物科技有限公司 表达αPDL1:Fc融合蛋白的间充质干细胞的制备及应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5785682A (en) 1995-03-22 1998-07-28 Abbott Laboratories Pre-filled syringe drug delivery system
WO1998048024A1 (en) * 1997-04-18 1998-10-29 Biogen, Inc. Type ii tgf-beta receptor/immunoglobulin constant region fusion proteins
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
BR0207854A (pt) 2001-03-07 2004-08-24 Merck Patent Gmbh Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
JP2005112812A (ja) * 2003-10-09 2005-04-28 Zeria Pharmaceut Co Ltd リン酸化部位特異的抗体及びそれを用いたスクリーニング方法
AU2004312049A1 (en) * 2003-12-24 2005-07-21 Scios, Inc. Treatment of malignant gliomas with TFG-beta inhibitors
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US7795389B2 (en) 2004-09-28 2010-09-14 The Board Of Regents Of The University Of Texas System Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
HUE026039T2 (en) 2005-07-01 2016-05-30 Squibb & Sons Llc Human monoclonal antibodies programmed for death ligand 1 (PD-L1)
CN101541832B (zh) * 2006-09-07 2014-11-12 克鲁塞尔荷兰公司 能中和流感病毒h5n1的人结合分子及其应用
EP2171062A1 (en) 2007-06-15 2010-04-07 Genzyme Corporation Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor
US20140127200A1 (en) 2008-01-03 2014-05-08 The Scripps Research Institute Multispecific Antibody Targeting and Multivalency Through Modular Recognition Domains
WO2009152610A1 (en) 2008-06-20 2009-12-23 The Royal Institution For The Advancement Of Learning/Mcgill University Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
EA201170031A1 (ru) 2008-07-02 2011-08-30 Эмерджент Продакт Дивелопмент Сиэтл, Ллс СВЯЗЫВАЮЩИЕ НЕСКОЛЬКО МИШЕНЕЙ БЕЛКИ, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКИМ ДЕЙСТВИЕМ ПО ОТНОШЕНИЮ К TGF-β
EP2376535B9 (en) 2008-12-09 2017-09-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
FR2944448B1 (fr) * 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
JP5873003B2 (ja) 2009-03-18 2016-03-01 アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． ＩｇＧデコイ受容体融合タンパク質の血液脳関門送達のための組成物および方法
EP2493929B1 (en) 2009-10-28 2017-08-16 AbbVie Biotherapeutics Inc. Anti-egfr antibodies and their uses
HUE049647T2 (hu) 2009-11-24 2020-09-28 Medimmune Ltd Targetált kötõdõ ágensek B7-H1 ellen
US20130129723A1 (en) * 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
ES2592385T3 (es) * 2009-12-29 2016-11-29 Aptevo Research And Development Llc Proteínas de unión a heterodímeros y usos de los mismos
TWI457135B (zh) 2010-02-23 2014-10-21 Genentech Inc 治療鉑敏感性復發性晚期上皮卵巢癌、輸卵管癌或原發性腹膜癌之卡鉑、吉西他濱與抗vegf抗體之組合
PT2542590T (pt) * 2010-03-05 2017-08-31 Univ Johns Hopkins Composições e métodos para anticorpos e proteínas de fusão imunomoduladores direcionados
TW201840336A (zh) * 2011-08-01 2018-11-16 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
NZ714549A (en) 2012-04-30 2016-10-28 Biocon Ltd Targeted/immunomodulatory fusion proteins and methods for making same
KR102129636B1 (ko) 2012-05-31 2020-07-03 제넨테크, 인크. Pd-l1 축 결합 길항제 및 vegf 길항제를 사용하여 암을 치료하는 방법
JP6720075B2 (ja) 2013-05-31 2020-07-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 癌のための併用療法
US20150190506A1 (en) 2013-12-17 2015-07-09 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
PE20210168A1 (es) 2014-02-10 2021-01-28 Merck Patent Gmbh INHIBICION DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGFß)
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20170036796A (ko) 2014-08-15 2017-04-03 메르크 파텐트 게엠베하 Sirp-알파 면역글로불린 융합 단백질

Also Published As

Publication number Publication date
US20200055949A1 (en) 2020-02-20
JP2020174674A (ja) 2020-10-29
RU2021114500A (ru) 2021-06-07
AU2019246876B2 (en) 2021-10-21
MX2021003685A (es) 2021-06-04
RU2016135062A3 (hr) 2018-12-12
US9676863B2 (en) 2017-06-13
EP3889172A1 (en) 2021-10-06
IL281565B (en) 2021-12-01
US20180002436A1 (en) 2018-01-04
KR102363008B1 (ko) 2022-02-16
CY1124408T1 (el) 2022-07-22
DK3105246T3 (da) 2021-06-14
RU2752424C2 (ru) 2021-07-28
ES2876430T3 (es) 2021-11-12
CN106103488B (zh) 2021-07-30
CA2934979A1 (en) 2015-08-13
EP3105246B1 (en) 2021-03-31
IL246968A0 (en) 2016-09-29
WO2015118175A3 (en) 2015-10-08
AU2015213988A1 (en) 2016-07-07
CN106103488A (zh) 2016-11-09
LT3105246T (lt) 2021-08-25
NZ721364A (en) 2023-04-28
BR112016014952A2 (pt) 2017-09-19
PH12016501549A1 (en) 2016-10-03
RU2016135062A (ru) 2018-03-15
DK3889172T3 (da) 2024-06-17
JP2017506217A (ja) 2017-03-02
MX2016010067A (es) 2016-10-07
AU2015213988B2 (en) 2019-07-11
US20150225483A1 (en) 2015-08-13
IL246968B (en) 2021-04-29
HUE054873T2 (hu) 2021-10-28
IL281565A (en) 2021-05-31
SI3105246T1 (sl) 2021-11-30
HRP20210977T1 (hr) 2021-09-17
SG11201606577YA (en) 2016-09-29
RS62038B1 (sr) 2021-07-30
KR20160119197A (ko) 2016-10-12
AU2022200365A1 (en) 2022-02-17
US20230056881A1 (en) 2023-02-23
JP6731346B2 (ja) 2020-07-29
CN113549159A (zh) 2021-10-26
PL3105246T3 (pl) 2021-11-29
EP3889172B1 (en) 2024-05-01
EP3105246A2 (en) 2016-12-21
AU2019246876A1 (en) 2019-10-31
WO2015118175A2 (en) 2015-08-13
PE20161096A1 (es) 2016-10-22
PT3105246T (pt) 2021-06-28
CL2016002017A1 (es) 2017-06-09
US11370819B2 (en) 2022-06-28
PE20210168A1 (es) 2021-01-28

Similar Documents

Publication Publication Date Title
IL281565B (en) Targeted inhibition of tgf-beta
IL304663A (en) combination
IL287113A (en) smyd inhibitors
IL247073A0 (en) combination
AU361515S (en) Dishrack
IL248895A0 (en) Phosphatidylinositol 3-kinase inhibitors
AU362944S (en) Lapboard
GB201409056D0 (en) Datacentre
GB201406989D0 (en) Novel treatments
PT3099317T (pt) Tripsina de bacalhau para utilização no tratamento de infeções microbianas num indivíduo com imunodeficiência
GB201412011D0 (en) Treatments
GB2532452B (en) Preventing browser-originating attacks
HK1196751A2 (en) Protective case
GB201401005D0 (en) Inhibitor
GB2559497B (en) Functional wall-tie
AU5583P (en) Lanminnesota Mandevilla sanderi
ZA201505557B (en) Protective arrangement
AU5286P (en) FLOMANWHW Mandevilla sanderi
AU5285P (en) FLOMANRER Mandevilla sanderi
AU5289P (en) FLOMANFOP Mandevilla sanderi
AU5288P (en) FLOMANTOG Mandevilla sanderi
AU5287P (en) FLOMANPIW Mandevilla sanderi
GB201415554D0 (en) Enzyme inhibition
GB201415549D0 (en) Enzyme inhibition
GB201420786D0 (en) Misfueling prevention device